Skip to main content
Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells

Fig. 1

Guadecitabine continuous treatment significantly reduces tumor growth. A schedule of treatments. B tumor volume reduction in mice treated with 1mg/kg guadecitabine (Guad) for 13 consecutive days (Day +13 p<0.01). n=5 mice/group. C significative reduction of mean tumor weight in mice receiving guadecitabine (Guad). *p<0.05. D no difference in mean mouse weight between control and treated mice

Back to article page